Friends publishes three white papers ahead of annual meetingTopics: Clinical trials on rare cancers, combination drug trials, multi-regional studies October 31, 2025Vol.51 No.40By Sara Willa Ernst
Trials & Tribulations How GLP-1RA drugs are reshaping patient physiology and the future of oncology October 31, 2025Vol.51 No.40By Deborah Phippard
Regulatory News Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLCctMoniTR project aims to improve efficiency in development of intermediate endpoints October 24, 2025Vol.51 No.39By Jacquelyn Cobb
Duke brain cancer researcher Kyle Walsh named director of NIEHS October 24, 2025Vol.51 No.39By Paul Goldberg
GRAIL to use new study results to seek FDA approval of Galleri MCD test October 24, 2025Vol.51 No.39By Jacquelyn Cobb
Omar Abdel-Wahab, John Byrd, Lieping Chen, Robert Ferris, Wendy Garrett, Victor Velculescu are among new members of National Academy of Medicine October 24, 2025Vol.51 No.39By Paul Goldberg
FreeTrials & Tribulations Experts warn that loss of carcinogen surveillance threatens to increase cancer incidence October 24, 2025Vol.51 No.39By David M. DeMarini, Rosalie Elespuru, Miriam C. Poirier and Errol Zeiger
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
News AnalysisRegulatory News How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough October 17, 2025Vol.51 No.38By Claire Marie Porter and Jacquelyn Cobb
Guest Editorial Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding October 17, 2025Vol.51 No.38By Todd Burus, Caree McAfee and Pamela C. Hull
